Grants Analysis Identification of MBC-Relevant Awards As of June 1, 2014, the ICRP database contained 18,755 grants that were active between the years of 2000 and 2013 and had been identified as being related to breast cancer studies; the HRA gHRAsp database contained 2045 grants that were active between the years of 2006 and 2013 and were related to breast cancer (see Figure 4). Using combinations of keywords (e.g., “metastasis, metastatic, advanced”) that would select for grants potentially relevant to MBC, the ICRP database yielded 2237 records and the HRA database yielded 73 records. We then manually reviewed a random sample of these grants to validate our search and data extraction strategy. Only 29 records were identified as being false positives—meaning that manual review of the record determined that it was irrelevant to MBC (around 1%). Thus, the keyword search strategy was effective in identifying relevant grants from both databases. The search yielded an MBC Grants dataset of 2281 grants totaling $1.07 billion. Examples of how grants were further categorized into the metastasis stage are given in Appendix 4. Figure 4: MBC Grants Dataset 29 false positives manual validation Grants categorized into: Molecular target/pathway Metastasis stage Model system/study type Basic/translational/clinical/cancer control Intervention (therapy, diagnostic, etc.) 18,775 awards $14.7B 2045 awards $0.7B 2310 awards 2281 awards $1.07B keyword search ICRP database: 18,755 awards ($14.7B) focused on breast cancer. Calendar years 2000–2013 HRA gHRAsp database: 2045 awards ($0.7B) focused on breast cancer. Calendar years 2006–2013 2310 awards potentially relevant to MBC with >50% of project relevant to breast cancer